SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a report that the company is preparing a potential takeover offer for eBay, fueling community speculation about a massive strategic shift and a possible short squeeze. While bulls are energized by the prospect of a high-stakes merger and potential gamma ramp, some investors remain skeptical about the financing feasibility and long-term viability of the deal.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing a significant surge in momentum as speculative traders position for a potential short squeeze ahead of its upcoming earnings report. With a high percentage of the float sold short and limited share availability, the community is actively rallying behind the stock, focusing on the potential for forced short covering and long-term growth in the AI sector.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following a Wall Street Journal report that GameStop is building a stake and weighing a potential acquisition of the e-commerce giant. While investors are debating the ambitious math behind a merger between the two companies, the community is actively discussing the feasibility of such a deal, potential deal structures, and whether this represents a long-term strategic pivot or an engineered short-term pump.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is attracting intense investor attention following positive pharmacokinetic data and emerging coverage for its flagship fibromyalgia treatment, Tonmya. Community discourse remains deeply divided between long-term bulls highlighting potential market expansion and vocal bears concerned about historical dilution, recurring reverse split proposals, and ongoing cash burn.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as the community highlights its ultra-low circulating supply and zero future dilution as key catalysts for potential price appreciation. Investors are actively discussing the possibility of a significant breakout should volume return to the asset, drawing parallels to its historical highs and comparing its tokenomics to larger cryptocurrencies.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2025 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is currently trending as a high-conviction buyout candidate, with investors actively discussing potential interest from major players like Netflix, Amazon, or Sony following the company's recent strategic spin-off. The community is heavily focused on the studio's strong IP library and the blockbuster box office potential of the Michael Jackson biopic as key catalysts that could drive a premium acquisition.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as community members focus on long-term accumulation and project utility, highlighting recent educational initiatives on their platform alongside bullish sentiment regarding future product developments. The community is actively rallying around the 'Wagmi' mindset, emphasizing project longevity and resilience as key drivers for potential recovery.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is drawing significant investor attention due to the upcoming launch of a new under $3 value menu and $4 breakfast deals, a strategic pivot aimed at reclaiming market share among budget-conscious consumers. While the community is actively debating the effectiveness of these pricing initiatives against rising operational costs and intense competition, the stock's defensive appeal continues to attract interest as a potential safe-haven asset in a volatile market.

Advanced Biomed, Inc. operates as a holding company with interests in developing biochip technologies. It engages in the research & development of microfluidic biochip technologies and provides tumor diagnosis and treatment technology applications. The company was founded by Yi Lu and Steven I-Fang Cheng in 2014 and is headquartered in Tainan, Taiwan.

Advanced Biomed Inc

Advanced Biomed is trending due to speculative momentum surrounding its low-float profile and recent clinical developments in precision medicine, with the community actively debating whether the stock is primed for a parabolic short squeeze or is simply a pump-and-dump scheme. Market participants are closely watching for potential breakout patterns as retail traders highlight low share supply as a catalyst for outsized price volatility.

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing extreme volatility and heavy retail attention as traders speculate on a potential short squeeze, despite significant skepticism regarding the stock's fundamentals and long-term sustainability. Community discourse is polarized, with many bulls looking for continued upward momentum and short-squeeze mechanics, while others caution against a possible rug pull as they monitor price action and short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Compass Pathways (CMPS) to Release Quarterly Earnings on Thursday

Compass Pathways (NASDAQ:CMPS) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

BIT Capital GmbH Raises Stock Holdings in Compass Pathways PLC Sponsored ADR $CMPS

BIT Capital GmbH increased its position in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 2,963.4% during the 4th quarter, according to the company in its most recent Form 13F...

Compass Pathways (NASDAQ:CMPS) Earns "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed a "buy" rating and set a $70.00 price target on shares of Compass Pathways in a report on Tuesday...

FDA Grants Quick Review Psychedelic Drugs, First Approvals Could Come As Soon As Summer

FDA Grants Quick Review Psychedelic Drugs, First Approvals Could Come As Soon As Summer

 The FDA announced new steps to speed up research on psychedelic treatments for serious mental health conditions, following an executive order from President Donald Trump directing agencies to expand...

Compass Pathways (NASDAQ:CMPS) Sees Large Volume Increase  - Here's Why

Compass Pathways (NASDAQ:CMPS) Sees Strong Trading Volume - Here's What Happened...

<ul class="summary-bullets"><li>CMPS stock has gained 41% this week, on track for its best week ever, if gains hold.&nbsp;</li><li>The voucher, aimed at fast-tracking therapies addressing major national health priorities, entitles Compass to enhanced FDA communications and a dramatically shortened review period for COMP360.</li><li>According to data from Koyfin, 11 of the 12 analysts covering CMPS rate it ‘Buy’ or higher, while one rates it ‘Hold.’</li></ul>Shares of Compass Pathways (CMPS ) climbed 5.5% on Friday, adding to a larger rally this week, after the company said that the U.S. Food and Drug Administration granted its synthetic psilocybin formulation the Commissioner's National Priority Voucher for treatment-resistant depression.CMPS stock has gained 45% this week, on track for its best week ever, if gains hold.The voucher, aimed at fast-tracking therapies addressing major national health priorities, entitles Compass to enhanced FDA communications and a dramatically shortened review period for COMP360, as little as 1-2 months after the application is filed.The company said that the agency has granted its rolling application request, allowing it to submit completed sections of its application rather than waiting for every section to be completed before review commences.Compass has conducted two late-stage studies for COMP360, generating data across more than 1000 patients with treatment-resistant depression. COMP360 may demonstrate effects as quickly as within one day after administration, with durability lasting at least through 6 months for those who achieve a clinically meaningful response after one or two doses, Compass said.<h2 class="st-heading-2">Trump’s Push For Psychedelics</h2>President Trump, over the last weekend, signed an executive order directing health agencies to speed up research on drugs like psilocybin and ibogaine.Earlier on Friday, the FDA also stated it will issue national priority vouchers to three companies studying psilocybin for the treatment of treatment-resistant depression and major depressive disorder, and methylone for the treatment of PTSD. However, Compass is the only publicly traded company in the U.S. among the three.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CMPS stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user expressed optimism for a further rally to $11.<stembedurl>https://www.stocktwits.com/texmade2/message/651311854</stembedurl>Another user opined that the market reaction to the priority review voucher announcement “feels too muted.”<stembedurl>https://www.stocktwits.com/ChristopherMcC/message/651309288</stembedurl>A third user termed the stock “super undervalued.”<stembedurl>https://www.stocktwits.com/Millionaire11/message/651299529</stembedurl>According to data from Koyfin, 11 of the 12 analysts covering CMPS rate it ‘Buy’ or higher, while one rates it ‘Hold.’ The stock has a 12-month average price target of $22.08, implying a potential upside of about 141% from the last closing price.On Friday, B. Riley initiated coverage of Compass Pathways with a ‘Buy’ rating and $17 price target. The company is on track to develop the first FDA-approved oral psychedelic drug for treatment-resistant depression, but the stock trades in the bottom percentile of its psychedelic peers, the analyst told investors in a research note.&nbsp;<a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> has gained 142% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-lidr-stock-surging-today/cZBh9Q3Rec0">LIDR Stock Surges 35% – This Analyst Sees Potential Returns Of 4-5x Over Time</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CMPS On Track For Best Week Ever On FDA Push For Psychedelics

Compass said on Friday that the FDA has granted its synthetic psilocybin formulation the Commissioner's National Priority Voucher for treatment-resistant depression.

Equity

Compass said on Friday that the FDA has granted its synthetic psilocybin formulation the Commissioner's National Priority Voucher for treatment-resistant depression.


Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug...

Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?

Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.

<ul class="summary-bullets"><li>The FDA stated that it will issue national priority vouchers to three companies studying psilocybin for the treatment of treatment-resistant depression and major depressive disorder, and methylone for the treatment of PTSD.</li><li>The agency stated that it has also cleared DemeRx NB’s early-stage clinical trial of noribogaine hydrochloride for potential treatment of alcohol use disorder to proceed following an Investigational New Drug submission.</li><li>Compass Pathways announced that it has been awarded a national priority voucher for COMP360, its proprietary formulation of synthetic psilocybin for treatment-resistant depression.</li></ul>The U.S. Food and Drug Administration (FDA) on Friday announced several regulatory actions to accelerate the development of psychedelic treatments aimed at serious mental health issues.The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.“Under President Trump’s leadership, we are accelerating the research, approval, and responsible access to promising mental health treatments—including psychedelic therapies like ibogaine—to confront our nation’s mental health crisis head-on, especially for our veterans,” said Health and Human Services Secretary Robert F. Kennedy, Jr.This comes after President Trump signed an executive order last week that directed health agencies to speed up research on drugs like psilocybin, MDMA, and ibogaine.Shares of&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences Inc.</a> (ENVB) skyrocketed over 62% in Friday morning’s trade, while&nbsp;<a href="https://stocktwits.com/symbol/CMPS">Compass Pathways Plc.</a> (CMPS) and&nbsp;<a href="https://stocktwits.com/symbol/HELP">Helus Pharma Inc.</a> (HELP) and&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences Inc.</a> (ENVB) rose between 2% to 3%.<h2 class="st-heading-2">FDA To Issue National Priority Vouchers</h2>The FDA stated that it will issue national priority vouchers to three companies studying psilocybin for the treatment of treatment-resistant depression and major depressive disorder, and methylone for the treatment of PTSD.Compass Pathways announced that it has been awarded a national priority voucher for COMP360, its proprietary formulation of synthetic psilocybin for treatment-resistant depression.The agency stated that it has also cleared an early-stage clinical trial of noribogaine hydrochloride for potential treatment of alcohol use disorder to proceed following an Investigational New Drug (IND) submission.This is the first time the FDA has permitted a U.S.-based clinical study of an ibogaine derivative, enabling the developer of the novel therapy, DemeRx NB, to initiate a Phase 1 trial in a closely monitored clinical setting in the United States.RFK Jr. said the agency will prioritize therapies with Breakthrough Therapy designation, for which early evidence shows meaningful improvement over existing options for serious mental illness.The agency stated that its decision allows the study to proceed and does not mean the drug has been approved or found to be safe or effective. FDA added that it will continue to review data as it becomes available and support efforts to develop new treatments for alcohol use disorder and other mental health conditions.<a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is up 36% year-to-date,&nbsp;<a href="https://stocktwits.com/symbol/HELP">HELP stock</a> is down 33%, while&nbsp;<a href="https://stocktwits.com/symbol/ENVB">ENVB stock</a> is up 77%.The AdvisorShares Psychedelics ETF (PSIL) is up 68% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dan-ives-intel-comeback-rocky-balboa-ai-trade-in-third-innings/cZBWzYEReTv">Dan Ives Compares Intel's Comeback To Rocky Balboa, Says AI Trade Is In Its Third Innings — 'You Follow The Capex, That's Where Investors Are'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump signs an executive order on researching the effects of psychedelic drugs in medical treatment for veterans. (Photo by Allison Robbert/For The Washington Post via Getty Images)

FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain

The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.

B. Riley Financial Initiates Coverage on Compass Pathways (NASDAQ:CMPS)

B. Riley Financial started coverage on Compass Pathways in a research report on Friday. They issued a "buy" rating and a $17.00 price objective on the stock...

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

CMPS
COMPASS Pathways

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CMPS News

CMPSCOMPASS Pathways